Evaluation of the BD OneFlow Acute Leukemia Panel on the BD FACSLyric Flow Cytometer

Last updated: August 5, 2024
Sponsor: Becton, Dickinson and Company
Overall Status: Completed

Phase

N/A

Condition

Leukemia

Treatment

IUO Acute Leukemia Panel

Clinical Study ID

NCT05035615
CAS-OFLYRICALL-IVDR
  • Ages > 3
  • All Genders

Study Summary

This study is a multi-site, prospective performance study to determine equivalency between the investigational OneFlow Acute Leukemia Panel on the FACSLyric system versus the final clinical diagnosis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Specimen collected/handled prior to enrollment in accordance with site policies andprocedures.

  2. Specimen with adequate volume (1 mL) to complete protocol tests.

  3. Specimen is leftover PB and BM from routine flow cytometry laboratory testing forhaving or suspected of having acute leukemia disorders (i.e. AML, BCP-ALL, ALAL,etc.), myelodysplastic syndrome (MDS), other hematological, or non-hematologicaldisorders.

  4. Specimen from newly diagnosed or relapsed subject.

  5. Only one specimen type (PB or BM) shall be enrolled per given subject.

  6. Specimen is stored at room temperature, upon receipt by the site.

  7. Specimens are collected in EDTA (K2 or K3) or heparin (sodium or lithium).

  8. Age of specimen (BCP ALL T1: time of collection to start of first pre-wash; ALOT,AML T1-T4: time of collection to start of staining): ≤ 24 hours.

  9. Specimens are from subjects irrespective of race, gender, and ethnicity

Exclusion

Exclusion Criteria:

  1. Specimen is from healthy subject.

  2. Specimen from subject <3 years of age.

  3. Specimen is from subject undergoing any treatment for any form of leukemia.

  4. Specimen is from subject with minimal residual disease (MRD) as determined by thesite.

  5. Specimen is from subject suspected of plasma cell disorders.

  6. Visibly clotted specimen.

  7. Visibly hemolyzed specimen.

  8. Frozen specimen.

  9. Refrigerated specimen.

  10. Fixed specimen.

Study Design

Total Participants: 332
Treatment Group(s): 1
Primary Treatment: IUO Acute Leukemia Panel
Phase:
Study Start date:
November 02, 2021
Estimated Completion Date:
July 18, 2024

Study Description

Hematology laboratories rely on flow cytometry technology (in addition to classic hematological methods) to aid in screening, diagnosing, and monitoring patients with hematological disorders. High speed and broad applicability of flow cytometry allows for the diagnosis. Currently, there are no consensus panels being used; consequently, the leukemia & lymphoma (L&L) testing remains a single-vial antibody being used, with various in-house laboratory developed tests (LDTs) being used to test patient specimens. Furthermore, the analysis of flow cytometer generated data is not standardized and requires a high level of expertise and training for interpretation of complex data. Therefore, optimized and standardized immunostaining protocols for the diagnosis, classification, and prognostic sub-classification of hematological malignancies are needed.

Enrollment will occur at up to 8 investigational sites . Data will be acquired from Eligible remnant/leftover specimens on the BD FACSLyric flow cytometer and evaluated by site personnel and expert analysts .

The final diagnosis and the affected cell population will be determined by site standard of care .

Analysis of data will evaluate identification of 1) normal vs abnormal cell populations and 2) BCP-ALL, AML, and less certain diseases by the expert & site analysts as compared to the final diagnosis.

Connect with a study center

  • Fleury Group

    San Paolo, 01323--020
    Brazil

    Site Not Available

  • Motol University Hospital, Childhood Leukemia Investigation

    Prague,
    Czechia

    Site Not Available

  • University of Salamanca

    Salamanca, 37007
    Spain

    Site Not Available

  • Cambridge University

    Cambridge, CB2 0QQ
    United Kingdom

    Site Not Available

  • Childrens Hospital Los Angeles

    Los Angeles, California 90027
    United States

    Site Not Available

  • New York-Presbyterian Hospital Weill Cornell Medicine

    New York, New York 10065
    United States

    Site Not Available

  • University Of North Carolina

    Chapel Hill, North Carolina 27514
    United States

    Site Not Available

  • CorePath Laboratories

    San Antonio, Texas 78229
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.